Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Insider & Institutional Ownership
87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 0.3% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Avalo Therapeutics and Silence Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avalo Therapeutics | N/A | -88.43% | -73.86% |
| Silence Therapeutics | -15,851.88% | -101.71% | -55.53% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avalo Therapeutics | 1 | 0 | 8 | 1 | 2.90 |
| Silence Therapeutics | 2 | 0 | 5 | 0 | 2.43 |
Avalo Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 95.04%. Silence Therapeutics has a consensus target price of $34.50, suggesting a potential upside of 450.24%. Given Silence Therapeutics’ higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Avalo Therapeutics.
Risk and Volatility
Avalo Therapeutics has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Valuation & Earnings
This table compares Avalo Therapeutics and Silence Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avalo Therapeutics | $440,000.00 | 711.79 | -$35.13 million | ($5.36) | -3.16 |
| Silence Therapeutics | $560,000.00 | 528.81 | -$88.61 million | ($1.87) | -3.35 |
Avalo Therapeutics has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Avalo Therapeutics beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.
About Avalo Therapeutics
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
